Showing results (151-160 of 369) with videos related to
Sort By:
Pageof 37
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.Journal of Circulating Biomarkers|March 15, 2021
Development of an immunofluorescent AR-V7 circulating tumor cell assay - A blood-based test for men with metastatic prostate cancerDavid Lu, Rachel Krupa, Melissa Harvey, et al.Cancer Chemotherapy and Pharmacology|July 4, 2013
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancerDana E Rathkopf, Joel Picus, Arif Hussain, et al.Radiology|January 31, 2014
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survivalHebert Alberto Vargas, Cecilia Wassberg, Josef J Fox, et al.JAMA Oncology|December 13, 2019
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical TrialsAndrew J Armstrong, Mohammed Al-Adhami, Ping Lin, et al.Investigational New Drugs|September 4, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genesKaren A Autio, Christos E Kyriakopoulos, Paul Palyca, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapyMichael J Morris, Timothy Akhurst, Steven M Larson, et al.The American Journal of Pathology|July 25, 2009
NF-kappaB regulates androgen receptor expression and prostate cancer growthLiying Zhang, Saleh Altuwaijri, Fangming Deng, et al.Cancer Immunology, Immunotherapy : CII|July 11, 2007
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"Susan F Slovin, Govind Ragupathi, Celina Fernandez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2010
Portable filter-based microdevice for detection and characterization of circulating tumor cellsHenry K Lin, Siyang Zheng, Anthony J Williams, et al.Pageof 37